Cytochrome P-450s are a superfamily of haem-containing proteins involved in the metabolism of foreign compounds, as well as a variety of endogenous molecules. The hepatic levels and function of this diverse group of enzymes are determined by both constitutive and xenobiotic regulators. To examine the role of constitutive factors in cytochrome P-450 regulation, the levels of three distinct groups of phenobarbitalinducible hepatic cytochrome P-450s were studied following dexamethasone-treatment or hypophysectomy.
INTRODUCTION
An increased ability to detoxify chemicals appears to be an important aspect of the biological evolutionary process. A major component of an organism's defence against chemical adversity is the superfamily of haemcontaining proteins termed cytochrome P-450s. These mono-oxygenases are found in most species and organs and are characterized by their broad substrate specificity (Lu & West, 1980) . In mammals, the major organ of chemical detoxification is the liver, where a multiplicity of distinct cytochrome P-450s have been identified. It has been known for some time that microsomal mono-oxygenases can be distinguished by their response to induction by foreign compounds (Ernster & Orrenius, 1965; Remmer & Merker, 1965) . This differential effect, together with developmental and sexual differences, has demonstrated the existence of multiple enzymes of overlapping substrate specificity. An estimate from protein purification data would suggest there are more than 13 forms of cytochrome P-450 in the rat liver (Waxman, 1986) . This view is supported by the molecular cloning of specific cytochrome P-450 cDNAs Wolf, 1986) .
Collectively, cytochrome P-450s represent a superfamily of enzymes with families of P-450 genes located on different chromosomes (Wolf, 1986; Nebert et al., 1987) . Several distinct families have been grouped on the basis of their sequence homology and regulation by xenobiotic inducers. These inducers include 2,3,7,8-tetrachlorodibenzo-p-dioxin (Gonzalez et al., 1985; Sogawa et al., 1985) (P-4501 family), phenobarbital (PB) (Atchison & Adesnik, 1983; Stupans et al., 1984 ) (P-45011 family), and pregnenolone-16a-carbonitrile (PCN) (Hardwick et al., 1984; Simmons et al., 1985) (P-450111 family). As recommended at the recent P-450 Gene Workshop we are using our previously used nomenclatures (Wolf, 1986; Wolf et al., 1986) . However, a new nomenclature has been proposed for the P-450 gene superfamily and these are listed in Nebert et al. (1987) . PB1 is a member of the family P-450IIC, PB2c is a member of sub-family P-4501II and PB3 is a member of the sub-family P-45011B. According to previous nomenclatures PBla is equivalent to PB1 described by Wolf et al. (1984) and Waxman & Walsh (1983) , PB2, is related to P-450s characterized by their induction by pregnenolone-16a-carbonitrile and PB3a is equivalent to a major phenobarbital-inducible P-450 described by Ryan et al. (1982) as form b. Proteins within family III can also be induced by synthetic glucocorticoids such as dexamethasone . The dose of dexamethasone required to induce these enzymes is 50-times greater than the dose required to activate the glucorticoid receptor ) and therefore appears to be by some other
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Vol. 254 789 mechanism. The actual mechanism of cytochrome P-450 regulation within families II and III however remains elusive. The use of mouse genetics has played an important role in identifying the mechanism of regulation of P-450s within family I (Nebert & Jensen, 1979) and represents a powerful approach for the study of P-450s within other families (Simmons et al., 1985; Noshira & Negishi, 1986) . We are at present developing this strategy to elucidate the constitutive factors involved in P-450 regulation. In this work we describe the effects of a synthetic glucocorticoid, dexamethasone, and hypophysectomy on mRNA and protein levels and activities of three P-450 subfamilies (P-45011B, P-4501IC and P-450III) in the mouse and rat liver.
MATERIALS AND METHODS
Male Wistar rats (200 g) or male CBA/Ca, BALB/c, C3H/He or C57BL/6 mice (25 g) were used. Animals were treated with either dexamethasone (20, 100 or 200 mg/kg, intraperitoneally in corn oil) or phenobarbital (80 mg/kg intraperitoneally in 0.9 % saline) on three consecutive days before use. Control animals received vehicle only. Animals were sacrificed by cervical dislocation and a sample of liver was rapidly excised and homogenized with guanidinium hydrochloride for the preparation of mRNA (see below). The remaining liver samples were homogenized in 1.15 5 % KCI, buffered with 10 mM-phosphate, pH 7.4. The preparation of microsomal fractions then followed conventional procedures. Microsomes were stored in 0.25 M-sucrose buffered with 10 mm phosphate, pH 7.4, at a protein concentration of 10-20 mg/ml, at -70°C before use. Protein determinations were made using the method of Lowry et al. (1951) and cytochrome P-450 reductase was determined as described previously (Adams et al., 1985) . The metabolism of the mono-oxygenase substrates, benzphetamine and pentoxy-and benzyloxy-resorufin was determined colorimetrically (Nash, 1953) or fluorimetrically (Burke et al., 1985) . Antibodies to the purified cytochrome P-450 isoenzymes (PBla, PB2c and PB3a) were prepared as described previously . Western blots were carried out using a,nodified version of the method reported by Towbin et al. (1979) and as described by Adams et al. (1985) with the following modifications: nitrocellulose filters were blocked with 3 % bovine serum albumin and exposed to antiserum (diluted 1:500) for 1 h. Bound antibody was visualized using either the peroxidase-antiperoxidase method using 4-chloro-1 -naphthol as substrate or 125I-protein A. Immunohistochemistry was carried out on frozen liver sections using the method described by Buchmann et al. (1985) and Wolf et al. (1984) .
Total liver RNA was extracted by the guanidine hydrochloride method (Cox, 1968) . RNA was subsequently fractionated on denaturing formaldehyde gels and analysed as described by Meehan et al. (1984) . cDNA probes were labelled either by the nick-translation or the random-priming method (Rigby et al., 1977; Feinberg & Vogelstein, 1983 . Hybridization and washing conditions were as described previously (Meehan et al., 1984) .
Materials
Resorufin analogues were purchased from Molecular Probes Inc., Junction City, OR, U.S.A. Emulgen 911 was a generous gift from the Kao-Atlas Company, Tokyo, Japan. Nitrocellulose filters were purchased from Schleicher and Schull, Dassel, Germany, and reagents for nick translations were purchased from BRL Ltd., Bethesda, MD, U.S.A. Other reagents were of high form f, a member of the PB1 (P-4501IC) subfamily, and pR17 to Levin form b, a member of the PB3a (P-450IIB) subfamily (Friedberg et al., 1986) . The clone pPCN12 was a cDNA of identical sequence to that described for the nifedipine oxidase cDNA (Beaune et al., 1986) Palmiter.
Activity analysis
The administration of dexamethasone to mice had a significant effect on the hepatic content of cytochrome P-450 and cytochrome P-450 reductase (Table 1) . In mice, dexamethasone (200 mg/kg) was almost as potent as phenobarbital in inducing both cytochrome P-450 and cytochrome P-450 reductase levels. In contrast, the levels of cytochrome P-450 were unchanged in rats following the same dexamethasone dose. However, the activity of cytochrome P-450 reductase was increased 1.6-fold.
Changes in mono-oxygenase activity following drug treatment are shown in (Fig. 1) . The effect on PB38 levels in the rat was variable, ranging from a suppression (Fig. 1) Studies were then carried out to establish whether the changes in cytochrome P-450 expression following administration of the two inducers could also be observed at the histochemical level. In addition, the localization of these cytochrome P-450s has not been reported for the mouse. In general, the changes in staining intensity mirrored those observed on Western-blot analysis. The localization of the cytochrome P-450 isoenzymes related to PB1a, PB2c and PB38 within livers of control animals was similar for mice and rats in that all isoenzymes were found preferentially in the centrilobular region (Fig. 2) . The assignment of centrilobular or periportal regions was based on the vessel structure observed at high magnification and was unequivocal. In the mouse the administration ofeither dexamethasone or phenobarbital led to a strong induction of all three P-450 isoenzymes. In the case of phenobarbital the induction was in the cells of central and mid-zonal regions of the liver acinus. The localization was not so clearly defined in the dexamethasone-treated animals (3 x 20 mg/kg). Although PB2. and PBla were predominantly localized in the centrilobular and mid-zonal regions, PB38 however, was more diffusely distributed through the liver lobule. In rats, only the staining intensity of PB2c was significantly elevated following dexamethasone administration Fig. 5. Induction of hepatic cytochrome P450 mRNA in mice following administration of dexamethasone and hypophysectomy Total RNA (10 g) was loaded per track. Samples were probed with the fQllowing cDNAs: pR17, subfamily IIB; pTF-1, subfamily IIC; pPCN.2, subfamily III. Composites were from the same blots, irrelevant bands being omitted. The animal treatments were: C, control; P, phenobarbital; Dex, dexamethasone; Hx, hypophysectomy. and that of PBla was unchanged. In both cases these proteins were more diffusely distributed through the liver lobule. When higher dexamethasone doses were used (3 x 100 mg/kg), it was interesting that the cells containmg the highest PBia concentration were changed from the centrilobular to the periportal region (Fig. 3) . The staining intensity in the experiment shown was elevated. However, this effect was variable and complicated by a change in liver structure (some necrosis and loss of cell structure) observed at high dexamethasone doses.
RNA analysis
The effect of dexamethasone on the levels of P-450 mRNA from subfamilies P-45011B, IIC and III were studied by Northern-blot analysis (Figs. 4 and 5) .
Dexamethasone induced PB2,-related mRNA in both rats and mice (5-to 10-fold). Control mice had very low basal levels of PB3-related mRNA (pR17) which were significantly induced by dexamethasone (10-to 20-fold). This induction was as great as that seen after phenobarbital treatment. In rats, the basal level of PB3 mRNA was higher, and variable, which made it difficult to assess the effects of dexamethasone treatment although there was an overall very slight induction. In both rats and mice phenobarbital and dexamethasone induced the levels of PB1 mRNA. The slight induction in mRNA levels in the rat is in contrast to the Western-blot data where dexamethasone apparently suppressed PB1 levels.
The induction of mouse liver mRNA by dexamethasone was time-dependent and required 24 h for maximal effect (Fig. 6) . It was much slower than the glucocorticoid receptor-mediated induction of metallothionein which was maximally induced after 4 h, indicating that different mechanisms are involved (Fig. 6 ).
The effect of hypophysectomy on the regulation of phenobarbital-inducible P-450 mRNA levels was also investigated, as this tissue has been reported to be involved in the regulation ofa variety ofsex-specific P-450 genes and is known to be affected by dexamethasone (Fig. 5) . A striking increase in mRNAs hybridizing to all three cDNA probes was observed on hypophysectomy in the mouse, the effect being as large, if not larger than phenobarbital or dexamethasone induction. This was particularly the case for the P-4501IC and P-450111 probes where mRNA levels were induced 10-to 20-fold. These effects were independent of the mouse strains used, i.e. CBA/Ca, BALB/c or C3H/He. In all samples, contrapsin mRNA level, which is known to be suppressed by hypophysectomy, was reduced (Hill et al., 1985) (results not shown). Hypophysectomy had essentially no effect on the levels of the P-450 mRNAs in the rat (results not shown). This difference between rats and mice was therefore similar to that observed on dexamethasone treatment.
DISCUSSION
Dexamethasone has profound effects on cytochrome P-450 expression as a single agent and in combination with other inducers. In our present study a number of observations on the effect of this compound on cytochrome P-450 levels can be made. (1) A difference between rats and mice in cytochrome P-450 regulation, analogous to that found here, has been reported for the compound 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) (Poland et al., 1981) . TCPOBOP is a potent inducer of benzphetamine metabolism in mice, a marker substrate for 'phenobarbital-like' induction, but has no effect in rats even at high doses. Whether TCPOBOP acts in a similar fashion to dexamethasone and has potentially 'glucocorticoidlike' properties remains to be established.
In spite of the similarities in the effects of hypophysectomy and dexamethasone it is not clear whether they act through a common mechanism. Initial studies indicate that dexamethasone and phenobarbitone will still induce hepatic P-450s in hypophysectomized mice (unpublished results) and also that the elevation in mRNA following hypophysectomy does not result in increased P-450 protein levels. However, factors produced in the pituitary can regulate phenobarbital-and dexamethasone-inducible P-450 mRNA in the mouse liver. This raises the intriguing question of why we have not made similar observations in the rat where no change in mRNA levels was observed on hypophysectomy.
This species difference was also found in the response to dexamethasone. In contrast to the mouse, only very slight changes in rat liver mRNA levels were observed for PB1 and PB3a following dexamethasone treatment. These findings are in contrast to those of Simmons et al. (1987) who found large increases in PB3a-related mRNA levels but no increase in PB3a protein. More recently Yamazoe et al. (1987) also reported slight changes in this mRNA species but, in contrast to the report of Simmons et al. (1987) , this increase was accompanied by elevated protein levels. This issue is therefore somewhat confused and it may be that constitutive PB3a levels, the dose, mode of administration, animal strain etc. may play a role in the response to this synthetic glucocorticoid in rats. In our studies PB1-related mRNA, however, did appear to be slightly induced in the rat by dexamethasone, but not translated. This response was, however, variable.
The finding that the PBl-related mRNA did not appear to be translated in the rat is intriguing in view of the change in PB1 localization following dexamethasone treatment. A change in hepatic morphology could explain these results, but the localization of other proteins was not affected by dexamethasone which argues against this. It may be that dexamethasone specifically induces certain members of the very extensive PB1 sub-family (Wolf, 1986; Wolf et al., 1986) , while suppressing the expression of others. The overall effect could be a reduction in PB1 content as seen on a Western blot. The fact that PB1 levels were significantly induced in the mouse would then explain why no change in localization was seen in this species.
There are many similarities in cytochrome P-450 isoenzyme composition between species and orthologous forms between rat, mouse, rabbit and human have been identified (Wolf, 1986) . However, it is clear that this gene superfamily has evolved very rapidly and in different species to different extents. The human P-450 superfamily, for example, seems less complex than that in small mammals (Meehan et al., 1988; Miles et al., 1988) . It therefore appears that in addition to the many similarities, significant differences between species in drug-metabolizing capacity must occur. As a consequence it is difficult to establish which model may best reflect the mechanism of isoenzyme regulation in man. It is however intriguing that synthetic, and possibly endogenous glucocorticoids have the potential to regulate major families of phenobarbital-regulated P-450s.
